{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T19:29:03Z","timestamp":1770838143709,"version":"3.50.1"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,17]],"date-time":"2026-01-17T00:00:00Z","timestamp":1768608000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T00:00:00Z","timestamp":1770768000000},"content-version":"vor","delay-in-days":25,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100004823","name":"Connecticut Department of Mental Health and Addiction Services","doi-asserted-by":"crossref","award":["n\/a"],"award-info":[{"award-number":["n\/a"]}],"id":[{"id":"10.13039\/100004823","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100004823","name":"Connecticut Department of Mental Health and Addiction Services","doi-asserted-by":"crossref","award":["n\/a"],"award-info":[{"award-number":["n\/a"]}],"id":[{"id":"10.13039\/100004823","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"crossref","award":["K23DA063650"],"award-info":[{"award-number":["K23DA063650"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Harm Reduct J"],"DOI":"10.1186\/s12954-026-01399-w","type":"journal-article","created":{"date-parts":[[2026,1,17]],"date-time":"2026-01-17T06:43:18Z","timestamp":1768632198000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Clinical outcomes from a mid-western opioid treatment program during covid-19 emergency regulations: a brief report on the effect of tetrahydrocannabinol (THC) use on take home methadone access"],"prefix":"10.1186","volume":"23","author":[{"given":"Erin T.","family":"LaCourt","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Oranu","family":"Ibekie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9510-5088","authenticated-orcid":false,"given":"Charles C.","family":"Dike","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6772-7149","authenticated-orcid":false,"given":"Oluwole","family":"Jegede","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,1,17]]},"reference":[{"key":"1399_CR1","unstructured":"Substance Abuse and Mental Health Administration. Methadone take-home flexibilities extension guidance. https:\/\/www.samhsa.gov\/medication-assisted-treatment\/statutes-regulations-guidelines\/methadone-guidance. Accessed Jan 14 2023."},{"key":"1399_CR2","unstructured":"Indiana General Assembly. Title 440 division of mental health and addiction.http:\/\/iac.iga.in.gov\/iac\/title440.html. Accessed Jan 10 2023."},{"key":"1399_CR3","unstructured":"Indiana General Assembly. IC 35-48-4-11 Possession of marijuana, hash oil, hashish, or salvia.https:\/\/iga.in.gov\/legislative\/laws\/2022\/ic\/titles\/035#35-48-4-11. Accessed July 27 2022."},{"key":"1399_CR4","unstructured":"Office of the Federal Register. Confidentiality of substance use disorder patient records. https:\/\/www.ecfr.gov\/current\/title-42\/chapter-I\/subchapter-A\/part-2. Accessed Nov 18 2022."},{"key":"1399_CR5","unstructured":"US Department of Health and Human Services. Health insurance portability and accountability Act of 1996. https:\/\/aspe.hhs.gov\/reports\/health-insurance-portability-accountability-act-1996. Accessed Nov 18 2022."},{"issue":"5","key":"1399_CR6","doi-asserted-by":"publisher","first-page":"e0232086","DOI":"10.1371\/journal.pone.0232086","volume":"15","author":"AM O\u2019Connor","year":"2020","unstructured":"O\u2019Connor AM, et al. Retention of patients in opioid substitution treatment: a systematic review. PLoS ONE. 2020;15(5):e0232086.","journal-title":"PLoS ONE"},{"issue":"2","key":"1399_CR7","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1176\/appi.ps.201300235","volume":"65","author":"CA Fullerton","year":"2014","unstructured":"Fullerton CA, et al. Medication-assisted treatment with methadone: assessing the evidence. Psychiatric Serv. 2014;65(2):146\u201357.","journal-title":"Psychiatric Serv"},{"issue":"2","key":"1399_CR8","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1111\/j.1360-0443.2009.02754.x","volume":"105","author":"P Blanken","year":"2010","unstructured":"Blanken P, et al. Outcome of long-term heroin-assisted treatment offered to chronic treatment-resistant heroin addicts in the Netherlands. Addiction. 2010;105(2):300\u20138.","journal-title":"Addiction"},{"issue":"29","key":"1399_CR9","doi-asserted-by":"publisher","first-page":"940","DOI":"10.15585\/mmwr.mm7129e2","volume":"71","author":"M Kariisa","year":"2022","unstructured":"Kariisa M, Davis NL, Kumar S, Seth P, Mattson CL, Chowdhury F, Jones CM, Jones CM, Compton WM, Han B, Baldwin G, Volkow ND. Vital signs: drug overdose deaths, by selected sociodemographic and social determinants of health characteristics\u201325 states and the district of Columbia, 2019\u20132020. MMWR Morb Mortal Wkly. 2022;71(29):940\u2013947. https:\/\/doi.org\/10.15585\/mmwr.mm7129e2.","journal-title":"MMWR Morb Mortal Wkly"},{"issue":"1","key":"1399_CR10","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1080\/08897077.2022.2060438","volume":"43","author":"LW Suen","year":"2022","unstructured":"Suen LW, Castellanos S, Joshi N, Satterwhite S, Knight KR. The idea is to help people achieve greater success and liberty: a qualitative study of expanded methadone take-home access in opioid use disorder treatment. Subst Abus. 2022;43(1):1143\u20131150.","journal-title":"Subst Abus"},{"issue":"9","key":"1399_CR11","doi-asserted-by":"publisher","first-page":"932","DOI":"10.1001\/jamapsychiatry.2022.1776","volume":"79","author":"CM Jones","year":"2022","unstructured":"Jones CM, Compton WM, Han B, Baldwin G, Volkow ND. Methadone-involved overdose deaths in the US before and after federal policy changes expanding take-home methadone doses from opioid treatment programs. JAMA Psychiatry. 2022;79(9):932\u2013934.","journal-title":"JAMA Psychiatry"},{"key":"1399_CR12","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsat.2021.108276","author":"MC Figgatt","year":"2021","unstructured":"Figgatt MC, Salazar Z, Day E, Vincent L, Dasgupta N. Take-home dosing experiences among persons receiving methadone maintenance treatment during COVID-19. J Subst Abuse Treat. 2021. https:\/\/doi.org\/10.1016\/j.jsat.2021.108276.","journal-title":"J Subst Abuse Treat"},{"key":"1399_CR13","unstructured":"Office of the Federal Register. Medications for the treatment of opioid use disorder. https:\/\/public-inspection.federalregister.gov\/2022-27193.pdf. Accessed Nov1 2023."},{"issue":"S2","key":"1399_CR14","doi-asserted-by":"publisher","first-page":"S112","DOI":"10.2105\/AJPH.2021.306654","volume":"112","author":"LW Suen","year":"2022","unstructured":"Suen LW, Coe WH, Wyatt JP, Adams ZM, Gandhi M, Batchelor HM, Castellanos S, Joshi N, Satterwhite S, P\u00e9rez-Rodr\u00edguez R, Rodr\u00edguez-Guerra E, Albizu-Garcia CE, Knight KR, Jordan A. Structural adaptations to methadone maintenance treatment and take-home dosing for opioid use disorder in the era of COVID-19. Am J Public Health. 2022;112(S2):S112\u20136.","journal-title":"Am J Public Health"},{"key":"1399_CR15","doi-asserted-by":"publisher","first-page":"114720","DOI":"10.1016\/j.psychres.2022.114720","volume":"315","author":"O Jegede","year":"2022","unstructured":"Jegede O, Rhee TG, Stefanovics EA, Zhou B, Rosenheck RA. Rates and correlates of dual diagnosis among adults with psychiatric and substance use disorders in a nationally representative U.S. Sample. Psychiatry Res. 2022;315:114720. https:\/\/doi.org\/10.1016\/j.psychres.2022.114720. Epub 2022 Jul 8. PMID: 35834863.","journal-title":"Psychiatry Res"}],"container-title":["Harm Reduction Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12954-026-01399-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12954-026-01399-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12954-026-01399-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T18:53:05Z","timestamp":1770835985000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12954-026-01399-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,17]]},"references-count":15,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1399"],"URL":"https:\/\/doi.org\/10.1186\/s12954-026-01399-w","relation":{},"ISSN":["1477-7517"],"issn-type":[{"value":"1477-7517","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,17]]},"assertion":[{"value":"29 August 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ethical approval was obtained from the Institutional Review Board at Saint Mary\u2019s College, Notre Dame, Indiana. Electronic Medical Record (EMR) access was granted after obtaining patient consent under federal regulations Title 42, Part 2 and HIPAA.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"32"}}